TX-FLUENCE
16.11.2023 15:50:34 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced it will have a major presence at MJBizCon, the leading cannabis industry conference. Fluence Cannabis Solutions Architect Casey Rivero will join a panel alongside Fluence customers to discuss how growers can maximize crop quality. In addition, the company is investing in connecting the cannabis community at this year’s conference, providing product demonstrations from Fluence’s line of leading LED lighting solutions as well as hosting a series of Grower Talks with Fluence experts at the company’s booth.
Moderated by MJBizDaily reporter Solomon Israel, Rivero’s session, entitled “Powering Through Market Conditions: How Growers in Established Markets are Doubling Down on Quality and Boosting Their Bottom-Line,” will provide growers with concrete steps they can take to navigate an uncertain market. Rivero, a former cannabis cultivator, will be joined by Travis Higginbotham, StateHouse vice president of cultivation; Chris Castle, COO and co-founder of Flora & Flame; Andrew Reich, division manager at SunMed Growers; and Tyler Smith, principal advisor at Smith Cultivations. The panel will take place from 10 to 10:40 a.m. PST on Thursday, Nov. 30 in room N259.
“Though I have had my own grows for years, I find myself learning every single day from the cultivators we collaborate with,” Rivero said. “I’m honored to sit beside some of the industry’s most successful and innovative growers and share our firsthand knowledge on what it takes to deliver the highest-quality product to the market.”
The company will also host a series of Grower Talks throughout the show at the Fluence booth (No. 43023). As part of the series, growers can learn about innovative HPS retrofitting strategies, intercanopy lighting solutions and other topics top of mind in the cannabis industry. Growers will have the opportunity to ask questions and solicit advice from experts in their field, including Taylor Kirk and Dr. Jason Matlock from Fluence's Horticulture Services division, as well as Dr. David Hawley, principal scientist and head of Fluence's Crop Research division. For a detailed list of sessions, including times and featured experts, visit Fluence’s social media the week of the show.
“MJBizCon is an opportunity for the brightest minds in cannabis to come together and share the latest innovations across every facet of the industry,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re looking forward to amplifying the voices of our customers as well as sharing insights from our in-house cannabis experts to showcase how Fluence’s LED technology can help cultivators grow smarter, more efficiently and at the highest quality.”
Fluence experts will also demo products from the company’s suite of LED technologies, including its RAPTR, VYPR, SPYDR, RAZR and VYNE fixtures—each designed to make cannabis growers’ lives easier. According to Fluence and Cannabis Business Times’ recently released “State of the Cannabis Lighting Market” report, growers are addressing ongoing industry challenges by redoubling their focus on crop quality. Fluence’s LED technology and cultivation expertise helps cannabis growers throughout the world improve bud density and quality and drive financial success.
For more information on Fluence, stop by the company’s MJBizCon booth in Las Vegas, No. 43023, between Nov. 28 and Dec. 1—or visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence-led.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116207472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom